Welcome to our dedicated page for Instil Bio news (Ticker: TIL), a resource for investors and traders seeking the latest updates and insights on Instil Bio stock.
Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company whose news flow centers on the development of novel therapies, with a particular focus on its lead asset AXN-2510, a PD-L1xVEGF bispecific antibody in development for multiple solid tumors. Company press releases and related SEC filings provide regular updates on clinical progress, collaborations, and financial results.
News about Instil Bio frequently covers clinical trial milestones for AXN-2510/IMM2510, including Phase 1 monotherapy studies in relapsed or refractory solid tumors and data from Phase 1 and Phase 2 studies in non-small cell lung cancer (NSCLC) conducted by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. in China. These updates have included preliminary safety and efficacy data, such as objective response rates and partial response rates in squamous and non-squamous NSCLC, as well as safety profiles in front-line NSCLC when ’2510 is combined with chemotherapy.
Investors and observers can also find corporate and financial updates in Instil Bio’s news, including quarterly financial results, operating expense details, and explanations of non-GAAP financial measures. Announcements have highlighted research and development spending, general and administrative expenses, and restructuring and impairment charges, along with reconciliations of GAAP to non-GAAP net loss and net loss per share.
Additional news items describe collaborations and corporate developments, such as the relationship with ImmuneOnco around ’2510, the role of Axion Bio, Inc. as a wholly-owned subsidiary dedicated to AXN-2510, leadership appointments including a Chief Medical Officer and board additions, and participation in healthcare conferences and investor events focused on the PD-(L)1xVEGF bispecific antibody landscape.
By following Instil Bio news, readers can track ongoing disclosures about AXN-2510’s clinical development, evolving collaboration arrangements, and the company’s financial and strategic updates as it advances its clinical-stage pipeline.
Instil Bio, Inc. (NASDAQ: TIL) announced its participation in two investor conferences this September. The first is the Morgan Stanley 19th Annual Global Healthcare Conference on September 9 at 2:00 p.m. ET, featuring a fireside chat. Following that, Instil will present at Baird’s 2021 Virtual Global Healthcare Conference on September 14 at 5:30 p.m. ET. Live webcasts of these events will be available on the company’s website, with archived recordings accessible after the events.
Instil Bio (NASDAQ: TIL) reported significant clinical advancements in its second quarter 2021 update. In a compassionate use study for advanced melanoma, 67% of patients showed an objective response, with 19% achieving a complete response. The lead asset, ITIL-168, received orphan drug designation from the FDA. Instil is on track to initiate a Phase 2 trial for ITIL-168 in H2 2021 and a Phase 1 trial for ITIL-306 in H1 2022. Financially, cash reserves increased to $566.7 million, supporting operations through 2023.
Instil Bio (Nasdaq: TIL) announced its management will present an overview at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 9:30 a.m. ET. Interested parties can access a live webcast at here. Instil is focused on developing TIL therapies, advancing products like ITIL-168 and ITIL-306 for cancer treatment, particularly advanced melanoma and solid tumors.
Instil Bio (NASDAQ: TIL) reported its Q1 2021 financial results, highlighting a strong IPO with $368 million gross proceeds completed in March 2021. The company is advancing its lead product, ITIL-168, which received orphan drug designation from the U.S. FDA for melanoma. As of March 31, 2021, cash and equivalents reached $609.6 million, allowing operations to be funded into 2023. R&D expenses significantly increased to $14.4 million from $2 million in Q1 2020. The company plans to initiate a Phase 2 trial for ITIL-168 in advanced melanoma in H2 2021.
Instil Bio (Nasdaq: TIL) has received orphan drug designation from the FDA for its ITIL-168 therapy, targeting melanoma stages IIB to IV. This designation provides incentives such as tax credits and market exclusivity for up to seven years upon approval. ITIL-168, an autologous cell therapy utilizing tumor infiltrating lymphocytes, aims to enhance treatment efficacy with a flexible manufacturing process. Instil plans to initiate a global phase 2 trial for advanced melanoma in 2021, with further trials for other solid tumors to follow in 2022.
Instil Bio (Nasdaq: TIL) presented encouraging clinical data for its tumor infiltrating lymphocyte therapy, ITIL-168, at the AACR meeting. In a compassionate use program involving 21 metastatic melanoma patients, 67% achieved an objective response, with 19% achieving complete response. Notably, all complete responders remained in remission at data cut-off, with remissions lasting from 30 to 80 months. The company plans to initiate a Phase 2 trial for ITIL-168 in advanced melanoma later this year, aiming for FDA and EMA submissions in 2023 and 2024, respectively.
Instil Bio, Inc. has successfully closed its initial public offering, issuing 18,400,000 shares of common stock at $20.00 per share, securing approximately $368.0 million in gross proceeds. This includes the underwriters’ full exercise of their option to purchase an additional 2,400,000 shares. The offering highlights Instil's commitment to advancing its cell therapy pipeline targeting cancer treatment. The shares are traded on the Nasdaq Global Select Market under the symbol TIL, with Morgan Stanley, Jefferies, and Cowen serving as joint book-running managers.
Instil Bio has priced its initial public offering (IPO) of 16,000,000 shares at $20.00 each, aiming to raise $320 million before fees. The shares will trade on Nasdaq under the symbol TIL, starting March 19, 2021, with the offering closing on March 23, 2021, subject to customary conditions. The underwriters hold an option for an additional 2,400,000 shares. The IPO is led by Morgan Stanley, Jefferies, and Cowen, with a prospectus available through these firms. Forward-looking statements caution potential investors about inherent uncertainties.